The development of novel diagnosis method for post-transplant acute rejection
Project/Area Number |
24591199
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Kidney internal medicine
|
Research Institution | Kobe University |
Principal Investigator |
NISHI Shinichi 神戸大学, 医学(系)研究科(研究院), 教授 (70251808)
|
Co-Investigator(Kenkyū-buntansha) |
SAITO Kazuhide 新潟大学, 大学院医学研究科・腎泌尿器病態学分野, 講師 (20262438)
|
Co-Investigator(Renkei-kenkyūsha) |
IMAI Naofumi 新潟大学, 大学院医学研究科・腎・膠原病内科学, 研究員 (50599165)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 急性拒絶反応 / 早期診断 / petraxin-3(PTX-3) / ボーダーライン / 抗体関連拒絶反応 |
Outline of Final Research Achievements |
Major cause of graft dysfunction is acute rejection (AR) and it affects to the graft survival. Available markers with high sensitivity and specificity other than serum creatinine are necessary for early diagnosis of AR. We evaluated the histological expression of an inflammatory marker; petraxin-3(PTX-3) and the amount of urine (PTX)-3 in AR cases. In AR cases including border line cases, PTX-3 expression of 5% and more indicated the current AR expression or predicted the future incidence of AR in border line cases. Unfortunately urine PTX-3 did not elevate in AR and border line cases. Histological expression of PTX-3 is an available maker for early diagnosis of AR.
|
Report
(4 results)
Research Products
(5 results)
-
[Journal Article] Pentraxin 3発現の、抗体関連型拒絶反応発症ABO血液型不適合移植腎2015
Author(s)
今井直史, 西慎一, 高橋香, 伊藤由美, 吉田一浩, 河野恵美子, 田崎正行, 中川由紀, 斎藤和英, 高橋公太, 成田一衛
-
Journal Title
日本臨床腎移植学会誌
Volume: 4
Pages: 1-4
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-